Document is current

Article History

Received: 5 February 2025

Accepted: 3 October 2025

First Online: 4 November 2025

Declarations

:

: The WiZen study received approval from the ethics commission of the TU Dresden (approval number: EK95022019). All data processing and analyses were conducted in compliance with the Declaration of Helsinki and the General Data Protection Regulation of the European Union.

: Not applicable.

: OS, VB, CB, and JS work in a university hospital with certified cancer centers, where MR also worked previously. They received grants from the Innovation Fund of the Federal Joint Committee when carrying out the study. Outside of the submitted work, JS received institutional grants for investigator-initiated research from the G-BA, the BMG, BMBF, the EU, the German Federal State of Saxony, Novartis, Sanofi, ALK, and Pfizer. He also took part in advisory board meetings as a paid consultant for Sanofi, Lilly, and the ALK. Outside of the submitted work, OS was a paid consultant for Novartis. He is also a member of the certification committee “Skin Cancer Centers” of the German Cancer Society and a member of the panel of experts for the project “Research into criteria to evaluate certificates and quality seals in accordance with Sec. 137a para. 3 sentence 2 No. 7 SGB V” for the Institute for Quality Assurance and Transparency in Healthcare (IQTIG). PW heads the DKG-certified Breast and Gynecological Cancer Center at the university hospital of the TU Dresden and is an additional member of the Board of Directors of NCT Dresden. PW receives institutional grants for investigator-initiated research from the DFG, Krebshilfe, Sächsische Aufbaubank (SAB), Gynäko-Onkologische Forschungsstiftung, Amgen, AstraZeneca, MSD, Novartis, Pfizer, Roche, Clovis, and GSK. PW receives honoraria as an advisory board member for Amgen, AstraZeneca, MSD, Novartis, Pfizer, Lilly, Roche, Teva, Eisai, Gilead, GSK, and Daiichi Sankyo. OO works in a certified breast cancer center, gynecologic cancer center, and oncologic center. OO is a member of the Executive Board of the German Cancer Society, head of the University Cancer Center Regensburg, and a member of the Board of Directors of CCC WERA. TL works in a certified breast and gynecologic cancer center. TP is head of a DKG-certified breast and gynecologic cancer center. St. Marien Amberg Medical Center is also an oncology center according to the criteria of the DKG. TL honoria: Amgen, Roche, Teva, Clovis, Tesaro, MSD, Novartis, Pfizer, Lilly, GSK, Gilead, Astra Zeneca, Daiichi Sankyo, Stemline, and Seagen; TL advisory boards: Amgen, MSD, Tesaro, Roche, Pfizer, Lilly, Myriad, Esai, GSK, Gilead, Daiichi Sankyo, Roche, Astra Zeneca; TL Travel Support: Pfizer, Pharma mar, MSD, Celgene, Roche, Astra Zeneca, Gilead, Daiichi Sankyo, and Stemline. All other authors have no relevant financial or non-financial interests to disclose. The design and interpretation were carried out independently and no interest group was able to influence them.